Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
Phase 1
18+
2 sites in TX, UT
What this study is about
This Phase 1 study is focused on people with breast cancer. The primary outcome being measured is Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs).
Simplified from trial records by PatientMatch.
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Assignment is predetermined by the study protocol.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs), Number of Participants with Dose-limiting Toxicity (DLT)
Secondary: Area Under the Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC[0-last]) of EXS74539, Duration of Response (DoR), Maximum Concentration (Cmax) of EXS74539, Objective Response Rate (ORR), Overall Survival (OS), Progression-free Survival (PFS), Time to Cmax (tmax) of EXS74539
Oncology, Respiratory